NICE
NICE rejects Pfizer blood cancer drug
July 16, 2013Sales and Marketing BMS, CML, NICE, Pfizer, bosulif
NICE is not recommending Pfizer’s blood cancer drug Bosulif due to uncertainties over its cost effectiveness and survival benefit. In …
NICE no for Celgene’s Revlimid
July 11, 2013Sales and Marketing Celgene, NICE, Revlimid
NICE has issued new draft guidance not recommending Celgene’s bone marrow disorder drug Revlimid over uncertainties of its efficacy. Revlimid …
Novartis’ Afinitor fails NICE test
July 8, 2013Sales and Marketing Afinitor, NHS, NICE, Novartis
Novartis’ breast cancer drug Afinitor (everolimus) has been knocked back by NICE as “it is not good value for money”. …
Lords: ‘Simplify pharma regulation’
July 1, 2013Sales and Marketing Lords, NICE, pharma, regulation
Investors are not putting their money into the UK’s regenerative medicine sector because of the high failure rate when it …
NICE finalises tamoxifen guidance
June 26, 2013Sales and Marketing Evista, NICE, lilly, tamoxifen
Women at risk of breast cancer can now be offered a daily pill on the NHS to stop the disease …
NICE completes Forxiga U-turn
June 26, 2013Sales and Marketing BMS, Forxiga, NICE
Bristol-Myers Squibb and AstraZeneca are celebrating after NICE reversed its decision from earlier this year and is now recommending their …
David Haslam: a new chairman for a new NICE
June 24, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Hasmam, NHS, NICE
When NICE was first set up in 1999, technology appraisals of new medicines were its sole focus, but over the …
CQC revelations continue
June 21, 2013Sales and Marketing CQC, NHS, NICE
The turmoil at the Care Quality Commission (CQC) shows no sign of abating as MPs may summon the current leadership …
Zaltrap ‘no’ from NICE
June 21, 2013Sales and Marketing NICE, Sanofi, Zaltrap
NICE is preparing to discard Sanofi’s Zaltrap as an NHS option for treating metastatic colorectal cancer (mCRC) that is resistant …
UK government keen to reduce drugs bill
June 21, 2013Sales and Marketing NHS, NICE, UK, VBP
The government has shown its hand in the drug pricing debate after asking for a 20% price cut on some …
Iluvien gets NHS nod
June 14, 2013Sales and Marketing Iluvien, NHS, NICE, alimera
NICE is gearing up to allow Alimera Sciences’ implant Iluvien to be used on the NHS as an option to …
NICE thumbs-up for Abilify
June 7, 2013Sales and Marketing Abilify, BMS, NICE, Otsuka
Adolescents who suffer from bipolar disorder should be treated on the NHS with Otsuka Pharmaceuticals’ Abilify, according to draft guidance …
NICE green light for Eylea
May 31, 2013Sales and Marketing Bayer, NICE, Regeneron
NICE has recommended Bayer’s injection Eylea as a treatment for neovascular (wet) age-related macular degeneration (AMD) if the manufacturer offers …
Bad pharma, good pharma: an insider’s view
May 30, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Bad pharma, Goldacre, NICE, transparancy
Most people in the pharmaceutical industry, particularly in the UK, will be well-acquainted with Ben Goldacre by now. He published his …
NICE U-turn on Forxiga
May 30, 2013Sales and Marketing Forxiga, NICE
NICE has recommended Bristol-Myers Squibb and AstraZeneca’s diabetes drug Forxiga in final draft guidance after turning its back on the …
